"COAGULATION FACTORS, INFLUENCED OR NOT, IN THE REPEATED DOSE TOXICITY TEST OF A CANDIDATE VACCINE AGAINST SARS-COV-2?"

Author:

Ancuța Diana-LarisaORCID, ,Preda MădălinaORCID,Muntean Andrei-AlexandruORCID, , ,

Abstract

"SARS-CoV-2 infection increases the risk of multi-organ systemic complications and venous and arterial thromboembolism. The development of vaccines has proven to be an effective method to combat severe forms of infection. Adverse effects reported after COVID-19 vaccination consisted of local injection site reaction, fatigue, myalgia, or fever as well as sporadic cases of vaccine-induced thrombotic immune thrombocytopenia, especially viral vector vaccines. Objectives: The aim of the study was to evaluate the repeated dose toxicity of a candidate vaccine against SARS-CoV-2, a test in which several parameters were analyzed, including coagulation factors. Materials and methods: The test included 120 rats, of both sexes, divided into six groups (main group, recovery group and control group) at which the human dose, 10X human dose and 1 control adjuvant were tested. The vaccine was administered intranasally, 4 times every two weeks. The final day was after the last administration to the main group and another 30 days from the last administration to the recovery group. On day 0 and the final day, blood was collected for hematological, biochemical, immunological examinations and coagulation tests (Fibrinogen, Prothrombin Time-PT, Activated Partial Thromboplastin Time-aPTT and Thrombin Time-TT). Results: Fibrinogen, in the case of all groups, increased on the final day, except for females from the recovery groups where this parameter decreased by 25%. PT, aPTT and TT, regardless of group or sex, had low values ​​compared to the initial time of the study. On day 0, the values ​​of the coagulation factors were homogeneous, the fibrinogen being between 155-347mg / dL, PT 25.5-57.8 sec, aPTT 61.9-120 sec and TT values ​​of 53-60 sec. On the final day, the group analysis also showed unit values. Fibrinogen increased between 90-116%, PT decreased by 48-71%, aPTT decreased by 59-80%, and TT had values ​​lower by 10-14% compared to the initial day. Conclusions: Increased fibrinogen associated with decreased PT and aPTT is common in human clinical pathology. Fibrinogen, PT, aPTT and TT are the standard parameters of blood clotting assessed in toxicity tests. The results obtained in the study represent a preliminary phase which, corroborated with the results of the other tests, supports the conclusion that the candidate vaccine does not have toxicological potential, the coagulation factors not being influenced after its repeated administration. Keywords: SARS-CoV-2, coagulation factors, rat, vaccine"

Publisher

Institutul National de Cercetare Dezvoltare Medico-Militara "Cantacuzino"

Subject

General Medicine

Reference27 articles.

1. "1. Guideline on repeated dose toxicity, 18 March 2010 CPMP/SWP/1042/99 Rev 1 Corr*Committee for Human Medicinal Products (CHMP).

2. 2. Martin Wehling. Principles of Translational Science in Medicine: From Bench to Bedside, Third Edition, ISBN 978-0-12-820493-1, Academic Press, 2021, doi.org/10.1016/C2019-0-01383-0.

3. 3. Forster R. Study designs for the nonclinical safety testing of new vaccine products. J Pharmacol Toxicol Methods. 2012;66(1):1-7. doi: 10.1016/j.vascn.2012.04.003.

4. 4. Charlene A. McQueen. Comprehensive Toxicology, Third Edition, Fifteen Volume Set. ISBN 978-0-08-100601-6. 2018. Elsevier Science

5. 5. Niu CY, Zhao ZG, Zhang YP, Hou YL, Li JJ, Jiang H, et al.. Exogenous normal lymph alleviates microcirculation disturbances and abnormal hemorheological properties in rats with disseminated intravascular coagulation. Braz J Med Biol Res. 2013;46(2):138-47. doi: 10.1590/1414-431x20122378.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3